Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.

Cancer immunology, immunotherapy : CII - 1 Aug 2016

Lee Sung-Eun, Lim Ji-Young, Ryu Da-Bin, Kim Tae Woo, Yoon Jae-Ho, Cho Byung-Sik, Eom Ki-Seong, Kim Yoo-Jin, Kim Hee-Je, Lee Seok, Cho Seok-Goo, Kim Dong-Wook, Lee Jong-Wook, Min Woo-Sung, Kim Myungshin, Min Chang-Ki

Abstract excerpt

Although the antimyeloma effect of lenalidomide is associated with activation of the immune system, the exact in vivo immunomodulatory mechanisms of lenalidomide combined with low-dose dexamethasone (Len-dex) in refractory/relapsed multiple myeloma (RRMM) patients remain unclear. In this study, we analyzed the association between immune cell populations and clinical outcomes in patients receiving Len-dex for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiogenesis Inhibitors

Share to Dexamethasone

Share to Disease Progression

Share to Lenalidomide

Share to Multiple Myeloma

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 27342591
DOI: 10.1007/s00262-016-1861-2
PMCID: PMC11029332

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.PMID 27342591Read ↗

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.Semantic proximity Read ↗

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.Semantic proximity Read ↗

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsSemantic proximity Read ↗

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trialSemantic proximity Read ↗

Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment.Semantic proximity Read ↗

Inflammatory microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myelomaSemantic proximity Read ↗

Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myelomaSemantic proximity Read ↗

Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.Semantic proximity Read ↗

Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma.Semantic proximity Read ↗

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaSemantic proximity Read ↗

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read ↗

Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.